Tetraphase Pharmaceuticals, Inc.
) recently announced that the first patient in its phase III
randomized, double-blind, double-dummy, multicenter, prospective
clinical study on eravacycline has been dosed. The candidate is
being developed for the treatment of complicated intraabdominal
Tetraphase intends to enrol 536 adults for the study in around
100 centers around the globe. Tetraphase will be evaluating the
efficacy, safety and pharmacokinetics (PK) of eravacycline in
Merck & Co. Inc.
) Invanz (ertapenem) in cIAI patients.
The primary objective of the study is clinical response at the
test-of-cure (TOC) visit in the microbiological intent-to-treat
(micro-ITT) patient population in the eravacycline arm as well as
in the Invanz cohort.
Tetraphase also expects to conduct a phase III study on
eravacycline for the treatment of complicated urinary tract
infections (cUTI). The company intends to commence the study by
Last year, the company successfully completed a phase II study on
eravacycline for the treatment of patients suffering from cIAI.
Results from the study revealed that eravacycline was active
against drug-resistant bacterial pathogens and demonstrated
infection cure rates in treating patients with cIAI. These
findings were similar to that of Invanz (the comparator drug used
in the trial). Eravacycline was also found to be safe during the
The company is also evaluating the candidate for other
indications. Eravacycline is the lead pipeline candidate at
Tetraphase. We expect investor focus to stay on the development
of the candidate.
Tetraphase presently carries a Zacks Rank #3 (Hold). Right now,
Gilead Sciences Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
GILEAD SCIENCES (GILD): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
TETRAPHASE PHAR (TTPH): Free Stock Analysis
To read this article on Zacks.com click here.